Navigation Links
ACEA Biosciences Hires Roger Luo as Vice President of Global Clinical Development
Date:2/28/2017

ACEA Biosciences, a pioneer in cell analysis instrumentation and the development of novel pharmaceuticals for the treatment of chronic diseases, has announced Dr. Roger (Feng) Luo as the new Vice President of Global Clinical Development. With more than 15 years of clinical development experience with a number of multinational drug companies, Dr. Luo will now team with Dr. Li Xu, Chief Medical Officer, and Dr. Xiao Xu, President, to continue advancing the company’s lead drug candidate, AC0010. The drug candidate is currently in clinical trials for the treatment of non-small cell lung cancer (NSCLC) in both China and the US. A pyrrolopyrimidine-based irreversible inhibitor of the EGFR tyrosine kinase, AC0010 provides NSCLC patients with a new treatment alternative should first generation EGFR tyrosine kinase inhibitors fail to produce a durable response. Thus far, AC0010 has demonstrated efficacy, tolerability, and safety in clinical trials in both China and the U.S. Global clinical trials are slated for late 2017.

Before joining ACEA, Dr. Luo was Compound Development Team Lead, and Senior Leadership Member of Exploratory Medicine and Early Development at Johnson & Johnson (JNJ). Prior to JNJ, he was the Sr. Director of Early Clinical Development at Daiichi-Sankyo, and Head of the Tumor Pharmacology Group at Bristol-Myers Squibb. In total, Dr. Luo has participated in more than 20 oncology drug development trials around the globe, and has particular expertise in lung cancer therapeutics. “We are thrilled to have Roger join ACEA at this critical phase of the company’s history,” said Xiao Xu. “Roger’s experience and proficiency in drug development will be a major asset as we usher AC0010 through clinical trials.”

For more information about ACEA Biosciences, click here.

For further information please contact:                                                                                    
ACEA Biosciences, Inc.                                                                                                                
Dr. Jeff Xue                                                                                                                                    
Phone: +1 858 724 0928 x 3075                                                                                                
email: jxue(at)aceabio(dot)com

Read the full story at http://www.prweb.com/releases/2017/03/prweb14105641.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related biology technology :

1. New Applications of Pressure BioSciences PCT Platform Prominently Featured at Scientific Conference on Technologies for Protein Research
2. Northstar Biosciences Launches All Natural Skincare Solutions
3. Further Advancements Made in the Development of an Improved Method For Rape Kit Testing Using Pressure BioSciences Patented Pressure Cycling Technology (PCT)
4. Sangamo BioSciences Announces Presentation At Regen Med Investor Day
5. Sangamo BioSciences Announces Presentation At The Needham Healthcare Conference
6. Centrillion Biosciences Announces Next-Gen Sequencing Innovation Grant Program
7. Quanta BioSciences qRT-PCR technology recommended in newly published CDC protocol for detection of H7N9 Avian Influenza
8. Regado Biosciences, Inc. Files Registration Statement for Proposed Initial Public Offering
9. Provitro Biosciences Awarded First-Ever U.S. Patent For Large-Scale Production Of Bamboo Plants
10. Neurocrine Biosciences To Present At The Bank of America Merrill Lynch 2013 Health Care Conference
11. Sangamo BioSciences Announces Presentation at the Bank of America Merrill Lynch 2013 Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... Personal eye wash is a basic first aid supply ... a time. So which eye do you rinse first if a dangerous substance enters both ... Duo Eye Wash with its unique dual eye piece. , “Whether its dirt and ...
(Date:10/11/2017)... ... 11, 2017 , ... Proscia Inc ., a data ... titled, “Pathology is going digital. Is your lab ready?” with Dr. Nicolas Cacciabeve, ... and how Proscia improves lab economics and realizes an increase in diagnostic confidence.* ...
(Date:10/11/2017)... LAGUNA HILLS, Calif. , Oct. 11, 2017 /PRNewswire/ ... London (ICR) and University of ... tool to risk-stratify patients with multiple myeloma (MM), in a ... . The University of Leeds is ... Myeloma UK, and ICR will perform the testing services to ...
(Date:10/11/2017)... ... October 11, 2017 , ... A new study published ... frozen and fresh in vitro fertilization (IVF) transfer cycles. The multi-center ... success. , After comparing the results from the fresh and frozen transfer cohorts, ...
Breaking Biology Technology:
(Date:4/11/2017)... , April 11, 2017 NXT-ID, Inc. ... technology company, announces the appointment of independent Directors Mr. ... to its Board of Directors, furthering the company,s corporate governance ... Gino ... we look forward to their guidance and benefiting from their ...
(Date:4/5/2017)... 2017 Today HYPR Corp. , leading ... component of the HYPR platform is officially FIDO® ... security architecture that empowers biometric authentication across Fortune 500 ... secured over 15 million users across the financial services ... home product suites and physical access represent a growing ...
(Date:4/3/2017)... , April 3, 2017  Data captured ... engineering platform, detected a statistically significant association ... prior to treatment and objective response of ... potential to predict whether cancer patients will ... treatment, as well as to improve both pre-infusion ...
Breaking Biology News(10 mins):